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Abstract We evaluated the role of Lck tyrosine kinase, an
early e¡ector of T cell activation, in regulation of the mem-
brane^cytoskeleton linker protein ezrin. Ezrin was constitutively
tyrosine phosphorylated in wild-type and CD45-de¢cient Jurkat
T cells, but not in Lck-de¢cient cells. However, phosphorylation
was evident in cells, in which Lck activity had been restored by
transfection. Phosphorylation was reduced by the Src family
kinase inhibitor PP2 and increased by the tyrosine phosphatase
inhibitor pervanadate, implying continuous tyrosine phosphory-
lation and dephosphorylation. Lck phosphorylated ezrin in vitro,
and the major phosphotyrosine was identi¢ed as Y145. These
results identify ezrin as the ¢rst cytoskeletal substrate for Lck.
/ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
T cell activation is initiated by recognition of an antigen/
MHC protein complex by the T cell receptor and a co-recep-
tor, such as CD4. Following receptor engagement, an intra-
cellular signal is generated by a set of receptor-associated
protein tyrosine kinases (PTKs). Among them the Src family
PTK Lck holds a key position as an early e¡ector of signal-
ing. The PTK substrates are in turn involved in further signal
propagation [1]. One of the early events after the onset of a
T cell signal is tyrosine phosphorylation of the membrane^
micro¢lament linker protein ezrin [2]. Recent ¢ndings argue
for a functional link between Lck and ezrin at the membrane^
cytoskeleton interface during the T cell activation [3,4]. How-
ever, many aspects in this connection are poorly character-
ized, including the possible direct regulation of ezrin by Lck.
The function of ezrin, or other ezrin^radixin^moesin
(ERM) family proteins, i.e. radixin or moesin, is regulated
in a complex manner, including phosphorylation of a C-ter-
minal threonine, PIP2 binding and tyrosine phosphorylation
[5]. Studies of the tyrosine phosphorylation of the ERM mem-
bers have been focused on ezrin. In epithelial cells phosphor-
ylation is induced upon stimulation of their PTK pathways
with growth factors, such as epidermal (EGF), platelet-de-
rived (PDGF) or hepatocyte growth factors (HGF) [6^8].
Both in T cells and in other cell types, the increase in tyrosine
phosphorylation is transient, indicating a dephosphorylation
of ezrin by a counteracting protein tyrosine phosphatase
(PTPase). The present study was undertaken to evaluate the
dependence of the tyrosine phosphorylation of ezrin on the
enzymatic activity of Lck.
2. Materials and methods
2.1. Cells
The Jurkat clones E6-1, J45.01 [9] and JCaM1.6 [10] were obtained
from the American type culture collection (ATCC, Rockville, MD,
USA), and JCaM1.6/Lck [11] was kindly provided by Dr. A. Weiss,
UCSF, CA, USA. For experiments the cells were grown to a density
of 0.5^1.0U106 cells/ml.
2.2. Antibodies
The ezrin rabbit antibody has been described [12]. The rabbit anti-
body to an N-terminal peptide of Lck was from Dr. T. Mustelin
(Burnham Institute, La Jolla, CA, USA). The horseradish peroxidase
(HRP)-conjugated monoclonal antibody (mAb) PY99 against phos-
photyrosine was from Santa Cruz Biotechnology (Santa Cruz, CA,
USA), and the HRP-conjugated secondary antibody to rabbit IgG
was from Amersham (UK).
2.3. Measurement of PTK activity
Cells were lysed in ice-cold TKB bu¡er (20 mM HEPES, pH 7.5,
1% NP-40, 150 mM NaCl, 5 mM EDTA) supplemented with 1 mM
sodium orthovanadate and protease inhibitors. Lck was immunopre-
cipitated with rabbit anti-Lck and protein A-Sepharose. The beads
were washed with the PTK reaction bu¡er (10 mM HEPES, pH
7.2, 5 mM MgCl2, 3 mM MnCl2). The reaction was done with
3 WM ATP, 1 Wg of the substrate poly(Glu/Tyr 4:1) and 5 WCi of
[Q-32P]ATP. After 15 min at 37‡C the reaction was stopped with 20
mM HEPES, pH 7.4, 40 mM EDTA, 2 mg/ml bovine serum albumin
on ice. After centrifugation the substrate was precipitated with tri-
chloroacetic acid and ¢lter-bound radioactivity measured. Speci¢c
counts were obtained by subtracting background values (pre-immune
serum) from total radioactivity.
2.4. Immunoprecipitation and immunoblotting
5U106 cells were lysed in RIPA bu¡er (10 mM Tris, pH 7.5, 50
mM NaCl, 0.5% sodium deoxycholate, 0.5% NP-40, 0.1% SDS), sup-
plemented with 1 mM sodium orthovanadate and protease inhibitors.
The lysates were cleared, pre-absorbed with protein A-Sepharose, and
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incubated with anti-ezrin or pre-immune serum. The immune com-
plexes were bound to protein A-Sepharose, washed and eluted with
1% SDS. Immunoprecipitates were separated by SDS^PAGE and
transferred to nitrocellulose ¢lters. Phosphotyrosine was detected
with PTyr mAb PY99-HRP. After stripping, ezrin was detected
with rabbit antibody and HRP-conjugated anti-rabbit IgG. Bound
HRP was detected using ECL. To test the e¡ect of PP2, 5U106 cells
at the density of 106 cells/ml were treated with 50 WM PP2 at 37‡C for
10 min. Control samples were treated with the PP2 solvent dimethyl
sulfoxide (6 0.1%).
2.5. Phosphorylation of ezrin in vitro
Placental ezrin was puri¢ed as described [6,13]. 2 Wg of ezrin was
phosphorylated in the PTK reaction bu¡er by puri¢ed human Lck
(Upstate Biochemical, Lake Placid, NY, USA) in the presence of 3 WM
ATP and 10 WCi of [Q-32P]ATP for 15 min at 37‡C.
2.6. Tryptic phosphopeptide mapping and Edman sequencing
In vitro phosphorylated ezrin was blotted on a polyvinylidene di-
£uoride ¢lter. The ¢lter piece containing phosphoezrin was excised,
blocked in 0.5% polyvinylpyrrolidone-360/100 mM acetic acid and
washed with 10% acetonitrile/H2O. Ezrin was digested overnight at
+37‡C with 1 Wg of sequencing grade modi¢ed trypsin in 10% ACN/
50 mM NH4HCO3, pH 8. Another 1 Wg of trypsin was added and the
incubation prolonged by 5 h. After the second digestion, residual
radioactivity was still retained in ¢lter. The digest was dried and
oxidized with performic acid and dissolved in the HTLE electropho-
resis bu¡er (formic acid:acetic acid:H2O, 50:156:1794, pH 1.9). Phos-
phopeptides were separated on a cellulose thin-layer plate, ¢rst by
electrophoresis and then by ascending chromatography in n-butanol:
pyridine:acetic acid:H2O, 750:500:150:600 v/v/v/v. Phosphopeptides
were detected by phosphoimager and recovered by elution with HTLE
bu¡er. Peptides were coupled to Sequelon-AA membranes, and Ed-
man degradation was performed on an ABI sequencer model 477A.
Released phenylthiohydantoin amino acid derivatives from each cycle
were spotted on TLC plates, and the radioactivity was quanti¢ed by
digital imaging after the subtraction of background. The phosphory-
lated amino acid was deduced by comparing to the predicted tryptic
peptides of ezrin.
2.7. Recombinant DNA constructs and fusion proteins
GST^ezrin fusion proteins were generated from full-length human
ezrin cDNA. For generation of the Y145F mutant fusion protein, a
double PCR method was used as described in [8]. All products were
veri¢ed by DNA sequencing. The fusion proteins were expressed in
Escherichia coli and puri¢ed using Glutathione Sepharose (Amersham
Pharmacia).
3. Results
3.1. Lck activity and expression of CD45 in Jurkat clones
The human T lymphoma cell line Jurkat and established
Jurkat clones with di¡erent Lck and CD45 activities were
used to evaluate the role of these signaling enzymes in the
regulation of ezrin in T cells. The wild-type clone E6-1, its
mutant derivatives JCaM1.6 lacking Lck activity, J45.01 de-
fective in the expression of CD45, and JCaM1.6/Lck, in which
Lck activity has been restored by transfection of mouse Lck,
were used. In order to set a ¢rm basis for the studies, we ¢rst
compared the PTK activity of Lck and the expression of
CD45 in the Jurkat clones.
Fig. 1. Lck activity in Jurkat clones. Immunocomplexed Lck from
di¡erent Jurkat clones was assayed for kinase activity using poly-
(Glu/Tyr 4:1) as a substrate. The results are expressed as mean spe-
ci¢c counts S S.D. of three experiments.
Fig. 2. Phosphorylation of ezrin in Jurkat clones with di¡erent Lck
activity. Ezrin was immunoprecipitated from Jurkat clones E6-1,
J.CaM1.6 and J.CaM1.6/Lck, and sequentially detected by pTyr
mAb and ezrin antiserum.
Fig. 3. E¡ects of pervanadate and PP2 on ezrin phosphorylation.
A: Ezrin was immunoprecipitated from Jurkat clones. The level of
tyrosine phosphorylated ezrin in control (3) or pervanadate-treated
cells (+) was evaluated by pTyr mAb reactivity. Ezrin antiserum
blot veri¢es loading of immunoprecipitates. B: Immunoprecipitated
ezrin from untreated cells (3) or cells treated with with Src family
kinase inhibitor PP2 (+) was evaluated by pTyr mAb reactivity. The
loading control as in A.
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High Lck activity was detected from clones E6-1 and
J45.01, whereas no activity was detectable from clone
JCaM1.6 (Fig. 1). As in a variety of CD45-de¢cient cells
[14], the total activity of Lck was even higher in J45.01 cells
than in the wild-type cells. In JCaM1.6/Lck cells the activity
was restored. The speci¢c counts between JCaM1.6/Lck and
other clones cannot be directly compared because immuno-
precipitations were performed with anti-human Lck antibody,
which may not react with equal a⁄nity with mouse Lck ex-
pressed in JCaM1.6/Lck cells. In additional assays a major
part of the Lck activity was found to be associated with the
membrane fraction in E6-1 and J45.01 cells (not shown).
These results con¢rmed the Lck-negativity of the clone
JCaM1.6 and the localization of a signi¢cant Lck activity at
the cell membrane in clones E6-1 and J45.01.
The level of cell surface expression of CD45 was evaluated
by £ow cytometry using mAb MEM-28, which recognizes all
CD45 isoforms. The expression of CD45 on the J45.01 cells
was about 7% of that on the clones E6-1 and JCaM1.6 (not
shown).
3.2. Tyrosine phosphorylation of ezrin in vivo
Ezrin was immunoprecipitated from each Jurkat clone,
probed with the anti-PTyr mAb PY99 on a Western blot ¢lter
and subsequently reprobed with ezrin antiserum to con¢rm
that an equal amount of protein was precipitated in each
sample (Fig. 2). A basal level of tyrosine phosphorylation
was detected in ezrin from clone E6-1, whereas no constitu-
tively phosphorylated ezrin was detected in the JCaM1.6 cells.
In the JCaM1.6/Lck clone, in which Lck activity was recon-
stituted, a signi¢cant amount of phosphotyrosine containing
ezrin was demonstrated, indicating a role of Lck in the phos-
phorylation of ezrin in T cells.
CD45 is the major tyrosine phosphatase of the T cell mem-
brane [15]. Therefore, we studied ezrin phosphorylation by
using the CD45-low Jurkat clone J45.01. In line with Lck
activity, a constitutive phosphorylation was observed (Fig.
3A). However, no hyperphosphorylation was detected. On
the other hand, when the cells were treated with 50 WM of
pervanadate, a PTPase inhibitor [16], the level of the tyrosine
phosphorylation of ezrin was elevated in both E6-1 and J45.01
Fig. 4. Lck-catalyzed phosphorylation of ezrin in vitro and identi¢cation of the major phosphorylation site. Placental ezrin, visualized by Coo-
massie staining (A, left lane) was phosphorylated by recombinant Lck (A, right lane). Two major phosphopeptides (a and b) from phosphopep-
tide mapping (B) were eluted and analyzed by quanti¢cation of 32P label released by successive cycles of Edman degradation (C). Both peptides
showed the same pattern (a=black bar, b=white bar). The phosphorylated amino acid was identi¢ed as tyrosine 145 by comparing to pre-
dicted tryptic peptides of ezrin sequence. D: The wild-type and Y145F ezrin were produced as GST fusions and phosphorylated by Lck. The
mutant form was less e⁄ciently phosphorylated than the wild-type protein. The amount of fusion proteins used in the experiment was detected
by Western blotting. A representative of three individual experiments is shown.
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cells (Fig. 3A). This e¡ect suggests that ezrin is constitutively
phosphorylated and dephosphorylated in these cells and that
pervanadate blocks the dephosphorylation step. However, we
have observed that the pervanadate treatment causes an al-
most two-fold increase in the activity of Lck in E6-1 cells
(data not shown), which also might contribute to the in-
creased phosphorylation. The increase seen in ezrin phosphor-
ylation in J45.01 cells in the presence of pervanadate could be
due to more e⁄cient phosphorylation by Lck or to the inhi-
bition of some other phosphatase than CD45. Interestingly,
pervanadate induced a detectable tyrosine phosphorylation of
ezrin also in JCaM1.6 cells (Fig. 3A), indicating that an alter-
native phosphorylation mechanism, in addition to Lck, exists
in Jurkat cells.
Experiments with the Src family selective PTK inhibitor
PP2 [17] provided further evidence for a direct role of Lck
in the constitutive phosphorylation of ezrin. When the E6-1 or
J45.01 cells were treated for 10 min with 50 WM PP2, the level
of tyrosine phosphorylation of ezrin was reduced (Fig. 3B).
The immediate decrease on the phosphorylation further sug-
gests that tyrosine phosphorylation of ezrin is e⁄ciently coun-
teracted by some PTPase(s) in the Jurkat cells.
3.3. Phosphorylation of ezrin in vitro
To study whether ezrin can directly be phosphorylated by
Lck, ezrin was puri¢ed from human placenta and mixed with
puri¢ed Lck in an appropriate PTK reaction bu¡er in the
presence of [Q-32P]ATP. After 15 min, the reaction was
stopped, proteins were separated on SDS^PAGE and ana-
lyzed. As shown in Fig. 4A, ezrin was readily phosphorylated
by Lck in this reaction.
The Lck-catalyzed phosphoezrin was subjected to two-di-
mensional tryptic phosphopeptide mapping. The signal was
accumulated in two major phosphopeptides with signi¢cantly
less activity in other peptides (Fig. 4B). The two phosphopep-
tides (a and b), which contain about 65% of the total radio-
activity, were further analyzed by Edman sequencing. The
majority of radioactivity was released by both peptides at
the third cycle of sequencing (Fig. 4C). Based on the predicted
tryptic cleavage sites in ezrin amino acid sequence, these pep-
tides represent modi¢cations of the same tryptic peptide,
143SGYLSSER150, the only peptide which contains a tyrosine
at position three. Thus, tyrosine 145 is the major residue phos-
phorylated by Lck. Similar ¢nding with two spots correspond-
ing to the same peptide was found when the Src-phosphory-
lation site in the PDGF beta-receptor was mapped [18]. The
result was further veri¢ed by producing wild-type and mutant
Y145F ezrin as GST fusion proteins, which were subjected to
in vitro phosphorylation by Lck. The wild-type was more
e⁄ciently phosphorylated than the mutant form (Fig. 4D).
4. Discussion
The Src family kinase Lck is an important signalling mol-
ecule mediating downstream e¡ects of TCR activation. Sev-
eral lines of evidence indicate that Lck acts as a direct regu-
lator of ezrin in Jurkat T cells. Ezrin is constitutively tyrosine
phosphorylated in the Jurkat clones E6-1 and J45.01, both of
which express a high PTK activity of Lck at the membrane,
whereas constitutive tyrosine phosphorylation of ezrin in the
clone JCaM1.6, which completely lacks Lck activity, is typi-
cally not detected. In this clone, reconstitution of Lck activity
by stable transfection restored the constitutive tyrosine phos-
phorylation of ezrin. The decrease in the phosphorylation
during a short treatment of cells with the Src family speci¢c
PTK inhibitor PP2 also argues for a role of Lck. Finally, in
vitro studies show that ezrin is a direct substrate for Lck.
Previous studies with A431 epidermoid carcinoma cells
have identi¢ed Y145 and Y353 as the major sites of tyrosine
phosphorylation of ezrin by the EGF receptor kinase [19]. We
have now shown that Y145 also acts as a target for Lck,
indicating that the phosphorylation by a receptor-type PTK
and by a Src family PTK bear overlapping functions in the
regulation of ezrin. Currently, not much is known on the role
of Y145 phosphorylation. Mutagenesis of both Y145 and
Y353 decreases the motogenic and morphogenic responses
of epithelial cells to the growth factor HGF [8]. Although
Y145 is the major site of Lck-catalyzed phosphorylation, it
is apparent that other tyrosine residue(s) are also phosphory-
lated to some extent, as Lck could phosphorylate Y145F-mu-
tated ezrin, albeit at a signi¢cantly lower level than the wild-
type protein. At present, we have no evidence for Y353 as a
target site for Lck, as (1) Y353 was not identi¢ed in the
phosphopeptide mapping, and (2) we did not see a decrease
in Lck-catalyzed in vitro phosphorylation of a double Y145F^
Y353F mutant GST^ezrin (data not shown).
The cytoskeletal e¡ects exerted by the Lck activation in
early T cell stimulation are, at least partially, mediated by
activation of the Rho family GEF Vav [20,21]. Whether tyro-
sine phosphorylation of ezrin is an alternative mechanism to
regulate dynamic changes of the actin cytoskeleton, as has
been suggested in EGF-, PDGF- or HGF-treated epithelial
cells [6^8], is still unclear. Alternatively, Lck-induced tyrosine
phosphorylation of ezrin may be linked to its other functions,
including participation in signaling pathways that control pro-
liferation and apoptosis [5].
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